Protective and Cross-Protective Efficacies of Inactivated Recombinant H5N1 and H5N8 Vaccines Against Highly-Pathogenic Avian Influenza H5-Type Strains in Chickens

Background Co-circulation of highly pathogenic avian influenza (HPAI) H5N1 and H5N8 viruses (clade 2.3.4.4b) threatens poultry production and public health, so vaccines that protect against both viruses are needed. This study evaluated the immunogenicity and cross-protective efficacy of inactivated recombinant (reverse genetics-derived) rgH5N1 and rgH5N8 vaccines (10 8.0 50% embryo infectious dose [EID 50 ]/dose) against homologous and heterologous HPAI H5-type challenge in specific-pathogen-free (SPF) chickens. Vaccine strains were inactivated with 0.2% formalin and emulsified with Montanide ISA 71 VG adjuvant. SPF chickens (n = 10 per group) received rgH5N1 (G1), rgH5N8 (G2), or phosphate-buffered saline (G3, unvaccinated controls). Hemagglutination inhibition (HI) titers were measured at weeks 2, 3, and 4 post-vaccination. At week 4, birds were challenged intranasally with homologous or heterologous HPAI virus (10 6 EID 50 /0.1 mL) and monitored for 10 days for clinical signs and mortality; viral shedding was assessed by real-time RT-PCR. Both vaccines induced HI responses that peaked at weeks 3–4. The rgH5N1 vaccine elicited high cross-reactive titers against H5N8 (9.2–9.4 log 2 ), whereas the rgH5N8 vaccine elicited lower cross-reactive titers against H5N1 (7.25 log 2 ). Both vaccines conferred 100% survival and no detectable viral shedding (cycle threshold [Ct] > 38) after homologous and heterologous challenge. All unvaccinated controls died, with high viral loads detected from day 3. Both inactivated vaccines provided complete cross-protection against heterologous H5-type challenge under controlled conditions, preventing mortality and detectable viral shedding. This supports their potential for controlling co-circulating H5N1 and H5N8 viruses in poultry, although confirmation in larger groups under field conditions is needed.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11243811/v1
Primary Topic
Influenza Virus Research Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Protective and Cross-Protective Efficacies of Inactivated Recombinant H5N1 and H5N8 Vaccines Against Highly-Pathogenic Avian Influenza H5-Type Strains in Chickens

Hassan Abushanab, Walid Hamdy Hassan, Mohamed N. F. Shaheen, Vinayak Brahmakshatriya et al.
1 links
Research Square
Influenza Virus Research Studies
preprint

Protective and Cross-Protective Efficacies of Inactivated Recombinant H5N1 and H5N8 Vaccines Against Highly-Pathogenic Avian Influenza H5-Type Strains in Chickens

Hassan Abushanab, Walid Hamdy Hassan, Mohamed N. F. Shaheen, Vinayak Brahmakshatriya, Adham Alkashef
preprint en

Abstract

Background Co-circulation of highly pathogenic avian influenza (HPAI) H5N1 and H5N8 viruses (clade 2.3.4.4b) threatens poultry production and public health, so vaccines that protect against both viruses are needed. This study evaluated the immunogenicity and cross-protective efficacy of inactivated recombinant (reverse genetics-derived) rgH5N1 and rgH5N8 vaccines (10 8.0 50% embryo infectious dose [EID 50 ]/dose) against homologous and heterologous HPAI H5-type challenge in specific-pathogen-free (SPF) chickens. Vaccine strains were inactivated with 0.2% formalin and emulsified with Montanide ISA 71 VG adjuvant. SPF chickens (n = 10 per group) received rgH5N1 (G1), rgH5N8 (G2), or phosphate-buffered saline (G3, unvaccinated controls). Hemagglutination inhibition (HI) titers were measured at weeks 2, 3, and 4 post-vaccination. At week 4, birds were challenged intranasally with homologous or heterologous HPAI virus (10 6 EID 50 /0.1 mL) and monitored for 10 days for clinical signs and mortality; viral shedding was assessed by real-time RT-PCR. Both vaccines induced HI responses that peaked at weeks 3–4. The rgH5N1 vaccine elicited high cross-reactive titers against H5N8 (9.2–9.4 log 2 ), whereas the rgH5N8 vaccine elicited lower cross-reactive titers against H5N1 (7.25 log 2 ). Both vaccines conferred 100% survival and no detectable viral shedding (cycle threshold [Ct] > 38) after homologous and heterologous challenge. All unvaccinated controls died, with high viral loads detected from day 3. Both inactivated vaccines provided complete cross-protection against heterologous H5-type challenge under controlled conditions, preventing mortality and detectable viral shedding. This supports their potential for controlling co-circulating H5N1 and H5N8 viruses in poultry, although confirmation in larger groups under field conditions is needed.

Research Square
Beni-Suef University (EG), National Research Centre (EG)
Good health and well-being
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon